267 related articles for article (PubMed ID: 25881117)
1. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.
Haney M; Ramesh D; Glass A; Pavlicova M; Bedi G; Cooper ZD
Neuropsychopharmacology; 2015 Oct; 40(11):2489-98. PubMed ID: 25881117
[TBL] [Abstract][Full Text] [Related]
2. Interaction between naltrexone and oral THC in heavy marijuana smokers.
Haney M; Bisaga A; Foltin RW
Psychopharmacology (Berl); 2003 Feb; 166(1):77-85. PubMed ID: 12491025
[TBL] [Abstract][Full Text] [Related]
3. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
[TBL] [Abstract][Full Text] [Related]
4. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.
Haney M
Neuropsychopharmacology; 2007 Jun; 32(6):1391-403. PubMed ID: 17091128
[TBL] [Abstract][Full Text] [Related]
5. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.
Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA
Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387
[TBL] [Abstract][Full Text] [Related]
6. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers.
Cooper ZD; Haney M
Psychopharmacology (Berl); 2010 Aug; 211(2):141-8. PubMed ID: 20490465
[TBL] [Abstract][Full Text] [Related]
7. What role does measuring medication compliance play in evaluating the efficacy of naltrexone?
Baros AM; Latham PK; Moak DH; Voronin K; Anton RF
Alcohol Clin Exp Res; 2007 Apr; 31(4):596-603. PubMed ID: 17374038
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.
Ray LA; Bujarski S; Courtney KE; Moallem NR; Lunny K; Roche D; Leventhal AM; Shoptaw S; Heinzerling K; London ED; Miotto K
Neuropsychopharmacology; 2015 Sep; 40(10):2347-56. PubMed ID: 25801501
[TBL] [Abstract][Full Text] [Related]
9. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.
Jayaram-Lindström N; Hammarberg A; Beck O; Franck J
Am J Psychiatry; 2008 Nov; 165(11):1442-8. PubMed ID: 18765480
[TBL] [Abstract][Full Text] [Related]
10. Effects of naltrexone on alcohol self-administration in heavy drinkers.
Davidson D; Palfai T; Bird C; Swift R
Alcohol Clin Exp Res; 1999 Feb; 23(2):195-203. PubMed ID: 10069545
[TBL] [Abstract][Full Text] [Related]
11. 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.
Arout CA; Cooper ZD; Reed SC; Foltin RW; Comer SD; Levin FR; Haney M
Addict Biol; 2021 Jul; 26(4):e12993. PubMed ID: 33389797
[TBL] [Abstract][Full Text] [Related]
12. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
Herrmann ES; Cooper ZD; Bedi G; Ramesh D; Reed SC; Comer SD; Foltin RW; Haney M
Psychopharmacology (Berl); 2016 Jul; 233(13):2469-78. PubMed ID: 27085870
[TBL] [Abstract][Full Text] [Related]
13. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration.
Newmeyer MN; Swortwood MJ; Abulseoud OA; Huestis MA
Drug Alcohol Depend; 2017 Jun; 175():67-76. PubMed ID: 28407543
[TBL] [Abstract][Full Text] [Related]
14. Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment.
Davidson D; Wirtz PW; Gulliver SB; Longabaugh R
Psychopharmacology (Berl); 2007 Sep; 194(1):1-10. PubMed ID: 17514344
[TBL] [Abstract][Full Text] [Related]
15. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
[TBL] [Abstract][Full Text] [Related]
16. Naltrexone alteration of the nicotine-induced EEG and mood activation response in tobacco-deprived cigarette smokers.
Knott VJ; Fisher DJ
Exp Clin Psychopharmacol; 2007 Aug; 15(4):368-81. PubMed ID: 17696684
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.
King A; Cao D; Vanier C; Wilcox T
Alcohol Clin Exp Res; 2009 Jun; 33(6):1044-50. PubMed ID: 19302083
[TBL] [Abstract][Full Text] [Related]
18. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
19. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients.
Baltieri DA; Daró FR; Ribeiro PL; Andrade AG
Drug Alcohol Depend; 2009 Nov; 105(1-2):33-41. PubMed ID: 19595518
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
